These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 18614864)

  • 1. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
    Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
    AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.
    Metzner KJ; Rauch P; von Wyl V; Leemann C; Grube C; Kuster H; Böni J; Weber R; Günthard HF
    J Infect Dis; 2010 Apr; 201(7):1063-71. PubMed ID: 20196655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J; Weber J; Machala L; Reinis M; Linka M; Brůcková M; Vandasová J; Stanková M; Konvalinka J
    Acta Virol; 2005; 49(1):29-36. PubMed ID: 15929396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
    Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
    Metzner KJ; Allers K; Rauch P; Harrer T
    AIDS; 2007 Mar; 21(6):703-11. PubMed ID: 17413691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany.
    Oette M; Kaiser R; Däumer M; Akbari D; Fätkenheuer G; Rockstroh JK; Stechel J; Rieke A; Mauss S; Schmalöer D; Göbels K; Vogt C; Wettstein M; Häussinger D
    Eur J Med Res; 2004 May; 9(5):273-8. PubMed ID: 15257882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
    de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
    J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.
    de Mendoza C; Rodriguez C; Corral A; del Romero J; Gallego O; Soriano V
    Clin Infect Dis; 2004 Oct; 39(8):1231-8. PubMed ID: 15486849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients.
    Masciotra S; Garrido C; Youngpairoj AS; McNulty A; Zahonero N; Corral A; Heneine W; de Mendoza C; García-Lerma JG
    AIDS; 2007 Nov; 21(18):2503-11. PubMed ID: 18025887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission.
    Delaugerre C; Morand-Joubert L; Chaix ML; Picard O; Marcelin AG; Schneider V; Krivine A; Compagnucci A; Katlama C; Girard PM; Calvez V
    Antivir Ther; 2004 Jun; 9(3):415-21. PubMed ID: 15259904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report.
    Capiluppi B; Saracco A; Gianotti N; Mussini C; Butini L; Tomasoni L; De Gennaro M; Rizzolo L; Monolo G; Cargnel A; Moioli C; Arici C; Portelli V; Rizzardini G; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):73-8. PubMed ID: 12003179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.
    Balduin M; Oette M; Däumer MP; Hoffmann D; Pfister HJ; Kaiser R
    J Clin Virol; 2009 May; 45(1):34-8. PubMed ID: 19375978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.